Microsatellite Instability as a Biomarker for PD-1Blockade微卫星不稳定性作为PD-1的生物标志物 封锁

Microsatellite Instability as a Biomarker for PD-1Blockade微卫星不稳定性作为PD-1的生物标志物 封锁

ID:40850017

大小:769.05 KB

页数:9页

时间:2019-08-08

Microsatellite Instability as a Biomarker for PD-1Blockade微卫星不稳定性作为PD-1的生物标志物 封锁_第1页
Microsatellite Instability as a Biomarker for PD-1Blockade微卫星不稳定性作为PD-1的生物标志物 封锁_第2页
Microsatellite Instability as a Biomarker for PD-1Blockade微卫星不稳定性作为PD-1的生物标志物 封锁_第3页
Microsatellite Instability as a Biomarker for PD-1Blockade微卫星不稳定性作为PD-1的生物标志物 封锁_第4页
Microsatellite Instability as a Biomarker for PD-1Blockade微卫星不稳定性作为PD-1的生物标志物 封锁_第5页
资源描述:

《Microsatellite Instability as a Biomarker for PD-1Blockade微卫星不稳定性作为PD-1的生物标志物 封锁》由会员上传分享,免费在线阅读,更多相关内容在学术论文-天天文库

1、ReviewClinicalCancerResearchMicrosatelliteInstabilityasaBiomarkerforPD-1Blockade1232,3JonathanC.Dudley,Ming-TsehLin,DungT.Le,andJamesR.EshlemanAbstractInitialresultsbyLeandcolleagues,whichwerepublishedinwithLynchsyndromeorsomatichypermethylationoftheMLH1theJune25,2015issueoftheNe

2、wEnglandJournalofMedicine,promoter.Theresultisacancerwitha10-to100-foldincreaseinreportsignificantresponsesofcancerswithmicrosatelliteinsta-mutations,associatedinthecolonwithpoordifferentiation,anbility(MSI)toanti–PD-1inhibitorsinpatientswhofailedintenselymphocyticinfiltrate,andasu

3、periorprognosis.Diag-conventionaltherapy.Thisfindingfitsintoabroaderbodyofnosticapproacheshaveevolvedsincetheearly1990s,fromresearchassociatingsomatichypermutationandneoepitoperelyingexclusivelyonclinicalcriteriatoincorporatingpathologicformationwithresponsetoimmunotherapy,withthea

4、ddedfeatures,PCR-basedMSItesting,andimmunohistochemistrybenefitofrelyingonasimple,widelyuseddiagnostictest.ThisforlossofMMRcomponentexpression.TumortypescanbereviewsurveysthepathogenesisandprognosticvalueofMSI,groupedintocategoriesbasedonthefrequencyofMSI,fromdiagnosticguidelinesf

5、ordetectingit,andthefrequencyofMSIcolorectal(20%)andendometrial(22%–33%)tocervical(8%)acrosstumors,withthegoalofprovidingareferenceforitsuseasandesophageal(7%)toskinandbreastcancers(0%–2%).abiomarkerforPD-1blockade.MSIusuallyarisesfromeitherIfinitialresultsarevalidated,MSItesting

6、couldhaveanexpandedgermlinemutationsincomponentsofthemismatchrepairroleasatoolinthearmamentariumofprecisionmedicine.(MMR)machinery(MSH2,MSH6,MLH1,PMS2)inpatientsClinCancerRes;22(4);813–20.Ó2016AACR.DisclosureofPotentialConflictsofInterestNopotentialconflictsofinterestweredisclosed.

7、Editor'sDisclosuresThefollowingeditor(s)reportedrelevantfinancialrelationships:J.R.Grandis—None.CMEStaffPlanners'DisclosuresThemembersoftheplanningcommitteehavenorealorapparentconflictsofinteresttodisclose.LearningObjectivesUponcompletionofthisactivity,theparticipantshouldhaveabett

8、erunderstandingofthepathogenesisandclini

当前文档最多预览五页,下载文档查看全文

此文档下载收益归作者所有

当前文档最多预览五页,下载文档查看全文
温馨提示:
1. 部分包含数学公式或PPT动画的文件,查看预览时可能会显示错乱或异常,文件下载后无此问题,请放心下载。
2. 本文档由用户上传,版权归属用户,天天文库负责整理代发布。如果您对本文档版权有争议请及时联系客服。
3. 下载前请仔细阅读文档内容,确认文档内容符合您的需求后进行下载,若出现内容与标题不符可向本站投诉处理。
4. 下载文档时可能由于网络波动等原因无法下载或下载错误,付费完成后未能成功下载的用户请联系客服处理。